United Therapeutics CEO Martine A. Rothblatt Sells 3,933 Shares (UTHR)
United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt unloaded 3,933 shares of United Therapeutics stock on the open market in a transaction dated Thursday, July 31st. The stock was sold at an average price of $90.95, for a total transaction of $357,706.35. Following the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $12,733. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics (NASDAQ:UTHR) traded down 1.57% during mid-day trading on Friday, hitting $89.51. 710,093 shares of the company’s stock traded hands. United Therapeutics has a 52-week low of $70.34 and a 52-week high of $116.65. The stock has a 50-day moving average of $90.92 and a 200-day moving average of $97.50. The company has a market cap of $4.231 billion and a P/E ratio of 17.57.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $8.38 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday. Separately, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday. Finally, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $102.33.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.